NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions ... While most current antipsychotics approved for schizophrenia work primarily ...

Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting ...

Helping patients and family members navigate behavioral and psychologic symptoms of dementia is a large part of providing care to people living with dementia.

Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The ...

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

While existing antipsychotic drugs primarily target dopamine receptors to manage schizophrenia symptoms, xanomeline-trospium chloride offers a novel approach by modulating cholinergic receptors.

Unlike previous antipsychotics, which target dopamine receptors in the brain, Cobenfy homes in on cholinergic receptors, the FDA said in its statement.

Antipsychotic drugs can increase the risk of diabetes, but dopamine receptors in the brain and body may be the key to a solution.

Learn about the different types of antipsychotics for schizophrenia, how they’re different, and how your doctor may decide which is best for you.

New University of Pittsburgh research points to a potential approach to reducing the risk of diabetes associated with widely-prescribed antipsychotic medications.

Taking antipsychotics can cause tardive dyskinesia to develop. Get expert answers on which medications carry a risk for tardive dyskinesia, how it's diagnosed, and how to reduce risk factors.